Purpose: This study was to assess the feasibility and cardio-protective effects of biocompatible silicon built restraint device (ASD) in rat’s heart failure (HF) model. Background: Ventricle restraint therapy (VRT) is a well-established and promising approach for management of advanced-stage dilated HF. Previous VRT devices offer a subjective level of restraint to the dilated heart muscles. However, the impact of the restraint nature, mesh tubular design and biocompatibility of VRT devices is not well investigated. Method: The performance and compliance of ASD were determined in vitro by adopting a pneumatic drive and ball burst test. SD rats were grouped into four (n=24); control, HF, ASD+HF and CSD+HF groups, respectively. HF was induced by left anterior descending artery ligation in all groups except the control group. ASD and CSD devices were implanted in the heart of ASD+HF and CSD+HF groups respectively. Results: The functional and expansion ability of ASD was observed to be safer and suitable to attenuate ventricular remodeling. ASD treated rats showed normal heart rhythm which was validated by a smooth -ST and asymmetrical T-wave. Hemodynamic parameters, and systolic and diastolic functions improved in the ASD+HF group and reduction in ventricular wall stress indicated reverse remodeling. Furthermore BNP values were reduced in ASD+HF group which confirmed ASD feasibility and reverse remodeling at a molecular level. ASD+HF group also showed no fibrosis thus proposing that ASD has its significant curative effects on the heart muscles. Conclusion: ASD was found to be a promising restraint therapy than the previously standard restraint therapies.